<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597307</url>
  </required_header>
  <id_info>
    <org_study_id>IN.PACT™ QoL PSR</org_study_id>
    <nct_id>NCT04597307</nct_id>
  </id_info>
  <brief_title>IN.PACT™ Quality of Life Post-Reimbursement Study</brief_title>
  <official_title>IN.PACT™ Quality of Life Post-Reimbursement Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively collect and assess the perception of health-related Quality of Life, Pain&#xD;
      and Walking Ability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To provide both the French National Authority for Health and the French Economic Committee&#xD;
      for Health Products requested information on patient-reported outcomes for the IN.PACT™&#xD;
      Admiral™ Drug-Coated Balloon. Patients will be followed using routine clinical practice and&#xD;
      the collection of two validated instruments: EuroQOL EQ-5D Quality of Life questionnaire and&#xD;
      the Walking Impairment Questionnaire (WIQ).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Quality of Life EQ-5D-5L French Index Score Change</measure>
    <time_frame>Baseline &amp; 12 months after endovascular procedure</time_frame>
    <description>Primary Objective: Assess the mean change of patient reported outcomes between pre-procedure visit (baseline) and 12 months after the endovascular procedure of the EQ-5D-5L Questionnaire using the French Index Score (from -0.530 to 1.000 with 1 being better) in the treatment of de novo PTA subjects with obstructive disease of peripheral arteries with the IN.PACT™ Admiral™ DCB.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking Ability Change</measure>
    <time_frame>Baseline &amp; 12 months after endovascular procedure</time_frame>
    <description>Primary Objective: Assess the mean change of patient reported outcomes between pre-procedure visit (baseline) and 12 months after the endovascular procedure of the Walking Impairment Questionnaire (WIQ) (0 to 100% with 100% being better) in the treatment of de novo PTA subjects with obstructive disease of peripheral arteries with the IN.PACT™ Admiral™ DCB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life EQ-5D-5L French Index Score Change Over Time</measure>
    <time_frame>Baseline, 30 days, 12 months and 24 months from the endovascular procedure</time_frame>
    <description>Assess the mean change of patient reported outcomes over time of EQ-5D-5L French Index Score (from -0.530 to 1.000 with 1 being better) collected at pre-procedure visit (baseline) and at 30 days, 12 months, and 24 months from the endovascular procedure in de novo patients treated with the IN.PACT™ Admiral™ DCB.&#xD;
In addition, the EQ-5D VAS Score (0 to 100 with 100 being better) will be assessed using the mean change between pre-procedure visit (baseline) and 12 months after endovascular procedure as well as the mean change over time collected at preprocedure visit (baseline) and at 30 days, 12 months, and 24 months from the endovascular procedure with the IN.PACT™ Admiral™ DCB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Ability Change Over Time</measure>
    <time_frame>Baseline, 30 days, 12 months and 24 months from the endovascular procedure</time_frame>
    <description>Assess the mean change of patient reported outcomes over time of the WIQ composite score (0 to 100% with 100% being better) collected at pre-procedure visit (baseline) and at 30 days, 12 months, and 24 months from the endovascular procedure in de novo patients treated with the IN.PACT™ Admiral™ DCB.&#xD;
In addition, the WIQ questions for Walking Impairment, Walking Distance, Walking Speed, and Stair Climbing will be assessed using the mean change between pre-procedure visit (baseline) and 12 months after endovascular procedure as well as the mean change over time collected at preprocedure visit (baseline) and at 30 days, 12 months, and 24 months from the endovascular procedure with the IN.PACT™ Admiral™ DCB.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obstructive Disease</condition>
  <condition>Atherosclerosis of Femoral Artery</condition>
  <condition>Atherosclerosis of Popliteal Artery</condition>
  <arm_group>
    <arm_group_label>IN.PACT™ Admiral™ DCB Cohort</arm_group_label>
    <description>De novo patients not previously treated with a DCB who are successfully treated with the IN.PACT™ Admiral™ DCB (ability to cross the target lesion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>IN.PACT™ Admiral™ Drug Coated Balloon (DCB)</intervention_name>
    <description>For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.</description>
    <arm_group_label>IN.PACT™ Admiral™ DCB Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients with obstructive disease of the peripheral arteries&#xD;
        that will have a percutaneous transluminal angioplasty (PTA) with the IN.PACT™ Admiral™&#xD;
        Drug Coated Balloon (DCB).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient or legally authorized representative provides written authorization and/or&#xD;
             consent per institution and geographical requirements&#xD;
&#xD;
          -  Patient has or is intended to receive or be treated with an eligible product&#xD;
&#xD;
          -  Patient is consented within the enrollment window of the treatment/therapy received&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who is, or is expected to be inaccessible for follow-up&#xD;
&#xD;
          -  Patient with exclusion criteria required by local law&#xD;
&#xD;
          -  Patient is currently enrolled in or plans to enroll in any concurrent drug and/or&#xD;
             device study that may confound results (i.e. no required intervention that could&#xD;
             affect interpretation of all-around product safety and or effectiveness)&#xD;
&#xD;
        Note: For this study, de novo patients will be enrolled to assess EQ-5D and WIQ at baseline&#xD;
        and follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Yann Goueffic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Paris St Joseph</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PSR Study Team</last_name>
    <phone>763-526-5668</phone>
    <email>rs.productsurveillanceregistry@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopitaux Universitaires Paris lle-France Ouest- Hopital Ambroise- Pare</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael Coscas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Gouny</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Clermont-Ferrand- Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Rosset</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Goueffic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Sapoval, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien Kaladji, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Rhena</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Goyault, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabil Chakfe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Sauguet, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

